1Akova M, Akalın HE. Nötropenik hastalarda ateş. Hacettepe Tıp Dergisi 1988; 21: 71-87.
2Akova M. Kanserli nötropenik hastaya yaklaşım. Hacettepe Tıp Dergisi 1995; 26: 31-6.
3Pizzo PA. Fever in immunosuppressed patients. N Engl J Med 1999; 341: 893-900.
4Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52: 56-93.
5Innes H, Lim SL, Hall A, Chan SY, Bhalla N, Marshall E. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer 2008; 16: 485-91.
6Paesmans M. Risk factors assessment in febrile neutropenia. Int J Antimicrob Agents 2000; 16: 107-11.
7Viscoli C, Bruzzi P, Castagnola E, Boni L, Calandra T, Gaya H, Meunier F, Feld R, Zinner S. Factors associated with bacteremia in febrile, granulocytopenic cancer patients. The International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer 1994; 30: 430-7.
8Kern WV. Risk assessment and risk-based therapeutic strategies in febrile neutropenia. Curr Opin Infect Dis 2001; 14: 415-22.
9Viscoli C, Castagnola E. Treatment of febrile neutropenia: What is new? Curr Opin Infect Dis 2002; 15: 377-82.
10Pizzo PA. Management of fever in patients with cancer and treatment induced neutropenia. N Engl J Med 1993; 328: 1323-32.
11Klastersky J. Therapy of infections in cancer patients. In: Klastersky J, Schimpff SC, Senn HJ (eds). Handbook of Supportive Care in Cancer. New York: Marcel Dekker Inc, 1995: 1-44.
12Kandemir Ö, Şahin E, Tiftik N, Kaya A. Febril nötropenik kanser hastalarında gözlenen infeksiyonlar ve tedavi başarısını etkileyen faktörlerin değerlendirilmesi. ANKEM 2006; 20: 98-102.
13Öztürk R. Febril nötropenide yeni etkenler ve antimikrobiklere karşı direnç. 3. Febril Nötropeni Mezuniyet Sonrası Eğitim Kursu Özet Kitabı. Ankara, 2004: 15-25.
14Wislinghoff H, Seifert H, Wenzel P, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003; 36: 1103-10.
15Akova M. Febril nötropenik hastalarda infeksiyon etkeni olarak gram-negatif bakterilerin dönüşü. 4. Febril Nötropeni Simpozyumu Program ve Özet Kitabı. Özet no. O-13. Antalya, 2001.
16Gaytan-Martinez J, Mateos-Garcia E, Sanchez-Cortes E, Gonzalez-Llaven J, Casanova-Cardiel LJ, Fuentes-Allen JL. Microbiological findings in febrile neutropenia. Arch Med Res 2000; 31: 388-92.
17Erman M, Akova M, Akan H, Korten V, Ferhanoğlu B, Köksal I, Cetinkaya Y, Uzun O, Unal S; Febrile Neutropenia Study Group of Turkey. Comparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: a prospective, randomized, multicenter study. Scand J Infect Dis 2001; 33: 827-31.
18Demiraslan H, Yıldız O, Kaynar L, Altuntaş F, Eser B, Aygen B. Febril nötropenik hastalardan izole edilen mikroorganizmalar ve antimikrobiyal duyarlılıkları: 2005 yılı verileri. Erciyes Tıp Dergisi 2007; 29: 376-80.
19Swati M, Gita N, Sujata B, Farah J, Preeti M. Microbial etiology of febrile neutropenia. Indian J Hematol Blood Transfus 2010; 26: 49-55.
20Vento S, Cainelli F. Infections in patients with cancer undergoing chemotherapy: etiology, prevention, and treatment. Lancet Oncol 2003; 4: 595-604.
21Paul M, Soares-Weiser K, Grozinsky S, Leibovici L. Betalactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst Rev 2003; 3: CD003038.
22Paul M, Borok S, Fraser A, Vidal L, Leibovici L. Empirical antibiotics against gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2005; 55: 436-44.
23Lindblad R, Rodjer S, Adriansson M, Andreasson B, Backstrom B, Johansson P, Karlsson K, Rhedin C, Turesson I. Empiric monotherapy for febrile neutropenia. A randomized study comparing meropenem with ceftazidime. Scand J Infect Dis 1998; 30: 237-43.
24Ozyilkan O, Yalcintas U, Baskan S. Imipenem-cilastatin versus sulbactam-cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients. Korean J Intern Med 1999; 14: 15-9.
25Paul M, Soares-Weiser S, Leibovici L. Beta-lactam monotherapy versus beta-lactam aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. Br Med J 2003; 326: 1111-9.
26Ferrara JJ, MacDougall C, Gallagher JC. Empiric antifungal therapy in patients with febrile neutropenia. Pharmacotherapy 2011; 31: 369-85.